Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2011

Open Access 01-12-2011 | Research

Pain in castration-resistant prostate cancer with bone metastases: a qualitative study

Authors: Adam Gater, Linda Abetz-Webb, Clare Battersby, Bhash Parasuraman, Stuart McIntosh, Faith Nathan, Elisabeth C Piault

Published in: Health and Quality of Life Outcomes | Issue 1/2011

Login to get access

Abstract

Background

Bone metastases are a common painful and debilitating consequence of castration-resistant prostate cancer (CPRC). Bone pain may predict patients' prognosis and there is a need to further explore CRPC patients' experiences of bone pain in the overall context of disease pathology. Due to the subjective nature of pain, assessments of pain severity, onset and progression are reliant on patient assessment. Patient reported outcome (PRO) measures, therefore, are commonly used as key endpoints for evaluating the efficacy of CRPC treatments. Evidence of the content validity of leading PRO measures of pain severity used in CRPC clinical trials is, however, limited.

Methods

To document patients' experience of CRPC symptoms including pain, and their impact on health-related quality of life (HRQL), semi-structured in-depth qualitative interviews were conducted with 17 patients with CRPC and bone metastases. The content validity of the Present Pain Intensity (PPI) scale from the McGill Pain Questionnaire (MPQ), and the 'Average Pain' and 'Worst Pain' items of the Brief Pain Inventory Short-Form (BPI-SF) was also assessed.

Results

Patients with CRPC and bone metastases present with a constellation of symptoms that can have a profound effect on HRQL. For patients in this study, bone pain was the most prominent and debilitating symptom associated with their condition. Bone pain was chronic and, despite being generally well-managed by analgesic medication, instances of breakthrough cancer pain (BTcP) were common. Cognitive debriefing of the selected PRO measures of pain severity highlighted difficulties among patients in understanding the verbal response scale (VRS) of the MPQ PPI scale. There were also some inconsistencies in the way in which the BPI-SF 'Average Pain' item was interpreted by patients. In contrast, the BPI-SF 'Worst Pain' item was well understood and interpreted consistently among patients.

Conclusions

Study findings support the importance of PRO measures of pain severity as key endpoints for evaluating the efficacy of treatments for CRPC, particularly for patients with bone metastases where episodes of BTcP are common. Qualitative evidence from CRPC patients supports the content validity of the BPI-SF ''Worst Pain' item and promotes use of this item for measuring pain severity in this population.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Shin H, Forman D, Mathers C, Parkin D: Cancer Incidence and Mortality Worldwide: IARC Cancerbase No10 [internet]. Lyon, France: International Agency for Research on Cancer; 2010. [http://​globocan.​iarc.​fr/​]
2.
Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, et al.: Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000, 31: 578–583. 10.1053/hp.2000.6698PubMedCrossRef
3.
Hering F, Rodrigues PR, Lipay M: Clodronate for treatment of bone metastases in hormone refractory prostate cancer. Int Braz J Urol 2003, 29: 228–233.PubMedCrossRef
4.
Collins R, Fenwick E, Trowman R, Perard R, Norman G, Light K, et al.: A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technol Assess 2007, 11: iii-xviii.
5.
6.
Saad F, Clarke N, Colombel M: Natural history and treatment of bone complications in prostate cancer. Eur Urol 2006, 49: 429–440. 10.1016/j.eururo.2005.12.045PubMedCrossRef
7.
Pinski J, Dorff TB: Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy. Eur J Cancer 2005, 41: 932–940. 10.1016/j.ejca.2004.12.026PubMedCrossRef
8.
Coleman RE: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27: 165–176. 10.1053/ctrv.2000.0210PubMedCrossRef
9.
Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, et al.: The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005, 16: 579–584. 10.1093/annonc/mdi122PubMedCrossRef
10.
Costa L, Major PP: Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 2009, 6: 163–174.PubMedCrossRef
11.
Armstrong AJ, Garrett-Mayer E, Ou Yang YC, Carducci MA, Tannock I, de WR, et al.: Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007, 25: 3965–3970. 10.1200/JCO.2007.11.4769PubMedCrossRef
12.
Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA, et al.: Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 2008, 26: 2544–2549. 10.1200/JCO.2007.15.0367PubMedCrossRef
13.
Apolone G, Corli O, Caraceni A, Negri E, Deandrea S, Montanari M, et al.: Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. Br J Cancer 2009, 100: 1566–1574. 10.1038/sj.bjc.6605053PubMedCentralPubMedCrossRef
14.
Deandrea S, Montanari M, Moja L, Apolone G: Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 2008, 19: 1985–1991. 10.1093/annonc/mdn419PubMedCentralPubMedCrossRef
15.
Cleeland CS: The measurement of pain from metastatic bone disease: capturing the patient's experience. Clin Cancer Res 2006, 12: 6236s-6242s. 10.1158/1078-0432.CCR-06-0988PubMedCrossRef
16.
Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al.: Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005, 113: 9–19. 10.1016/j.pain.2004.09.012PubMedCrossRef
17.
Jensen MP, McFarland CA: Increasing the reliability and validity of pain intensity measurement in chronic pain patients. Pain 1993, 55: 195–203. 10.1016/0304-3959(93)90148-IPubMedCrossRef
18.
Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS: When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995, 61: 277–284. 10.1016/0304-3959(94)00178-HPubMedCrossRef
19.
Melzack R: The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975, 1: 277–299. 10.1016/0304-3959(75)90044-5PubMedCrossRef
20.
Melzack R: The short-form McGill Pain Questionnaire. Pain 1987, 30: 191–197. 10.1016/0304-3959(87)91074-8PubMedCrossRef
21.
22.
Turk DC, Dworkin RH, Burke LB, Gershon R, Rothman M, Scott J, et al.: Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations. Pain 2006, 125: 208–215. 10.1016/j.pain.2006.09.028PubMedCrossRef
23.
Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al.: Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008, 9: 105–121. 10.1016/j.jpain.2007.09.005PubMedCrossRef
24.
US Department of Health and Human Services FaDA, Centre for Drug Evaluation and Research, Centre for Biologics Evaluation and Research, Centre for Devices and Radiological Health: Guidance for Industry: Patient-reported outcome measures: use in medical product development to support labelling claims. 2009.
25.
Rothman M, Burke L, Erickson P, Leidy NK, Patrick DL, Petrie CD: Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report. Value Health 2009, 12: 1075–1083. 10.1111/j.1524-4733.2009.00603.xPubMedCrossRef
26.
Eton DT, Shevrin DH, Beaumont J, Victorson D, Cella D: Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer. Value Health 2010, 13: 613–623. 10.1111/j.1524-4733.2010.00702.xPubMedCrossRef
27.
Lindqvist O, Rasmussen BH, Widmark A: Experiences of symptoms in men with hormone refractory prostate cancer and skeletal metastases. Eur J Oncol Nurs 2008, 12: 283–290. 10.1016/j.ejon.2008.03.003PubMedCrossRef
28.
Glaser B, Strauss A: The constant comparative methods of qualitative analysis. In Discovery of Grounded Theory. Aldine de Gruyter; 1967:101–116.
29.
Bowen G: Grounded theory and sensitizing concepts. Int J Qual Meth 2006, 1–9.
30.
Lasch KE, Marquis P, Vigneux M, Abetz L, Arnould B, Bayliss M, et al.: PRO development: rigorous qualitative research as the crucial foundation. Qual Life Res 2010, 19: 1087–1096. 10.1007/s11136-010-9677-6PubMedCentralPubMedCrossRef
31.
Guest B, Bunce A, Johnson L: How many interviews are enough? An experiment with data saturation and variability. Field Methods 2006, 18: 59–82. 10.1177/1525822X05279903CrossRef
32.
Francis JJ, Johnston M, Robertson C, Glidewell L, Entwistle V, Eccles MP, et al.: What is an adequate sample size? Operationalising data saturation for theory-based interview studies. Psychol Health 2010, 25: 1229–1245. 10.1080/08870440903194015PubMedCrossRef
33.
Gleason D: The Veterans Administration Coopertative urological Research Group: histologic grading and clinical staging of prostatic carcinoma. In Urological Pathology: The Prostate. Edited by: Tannenbaum M. Lea and Febiger; 1977:171–198.
34.
Tofthagen C: Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 2010, 14: E22-E28. 10.1188/10.CJON.E22-E28PubMedCrossRef
35.
Bennett D, Burton AW, Fishman S, Fortner B, McCarberg B, Miaskowski C, et al.: Consensus panel recommendations for the assessment and management of breakthrough pain: Part I Assessment. P & T 2005, 30: 297–301.
36.
Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G: The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009, 13: 331–338. 10.1016/j.ejpain.2008.06.014PubMedCrossRef
37.
Rothman ML, Beltran P, Cappelleri JC, Lipscomb J, Teschendorf B: Patient-reported outcomes: conceptual issues. Value Health 2007,10(Suppl 2):S66-S75.PubMedCrossRef
38.
Shi Q, Wang XS, Mendoza TR, Pandya KJ, Cleeland CS: Assessing persistent cancer pain: a comparison of current pain ratings and pain recalled from the past week. J Pain Symptom Manage 2009, 37: 168–174. 10.1016/j.jpainsymman.2008.02.009PubMedCentralPubMedCrossRef
39.
Harris K, Li K, Flynn C, Chow E: Worst, average or current pain in the Brief Pain Inventory: which should be used to calculate the response to palliative radiotherapy in patients with bone metastases? Clin Oncol (R Coll Radiol) 2007, 19: 523–527. 10.1016/j.clon.2007.04.007CrossRef
40.
Williamson A, Hoggart B: Pain: a review of three commonly used pain rating scales. J Clin Nurs 2005, 14: 798–804. 10.1111/j.1365-2702.2005.01121.xPubMedCrossRef
41.
Nunnally J: Pyschometric Theory. 2nd edition. New York: McGraw Hill; 1978.
42.
Brunelli C, Zecca E, Martini C, Campa T, Fagnoni E, Bagnasco M, et al.: Comparison of numerical and verbal rating scales to measure pain exacerbations in patients with chronic cancer pain. Health Qual Life Outcomes 2010, 8: 42. 10.1186/1477-7525-8-42PubMedCentralPubMedCrossRef
43.
Mathias SD, Crosby RD, Qian Y, Jiang Q, Dansey R, Chung K: Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form. J Support Oncol 2011, 9: 72–78. 10.1016/j.suponc.2010.12.004PubMedCrossRef
44.
Atkinson TM, Mendoza TR, Sit L, Passik S, Scher HI, Cleeland C, et al.: The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations. Pain Med 2010, 11: 337–346. 10.1111/j.1526-4637.2009.00774.xPubMedCentralPubMedCrossRef
45.
Twycross R, Harcourt J, Bergl S: A survey of pain in patients with advanced cancer. J Pain Symptom Manage 1996, 12: 273–282. 10.1016/S0885-3924(96)00149-2PubMedCrossRef
46.
Hwang SS, Chang VT, Fairclough DL, Kasimis B: Development of a cancer pain prognostic scale. J Pain Symptom Manage 2002, 24: 366–378. 10.1016/S0885-3924(02)00488-8PubMedCrossRef
47.
Maltoni M, Scarpi E, Modonesi C, Passardi A, Calpona S, Turriziani A, et al.: A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Support Care Cancer 2005, 13: 888–894. 10.1007/s00520-005-0807-6PubMedCrossRef
48.
Di LG, Autorino R, Perdona S, De Laurentiis M, D'Armiento M, Cancello G, et al.: Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. Eur Urol 2007, 52: 1020–1027. 10.1016/j.eururo.2007.02.060CrossRef
Metadata
Title
Pain in castration-resistant prostate cancer with bone metastases: a qualitative study
Authors
Adam Gater
Linda Abetz-Webb
Clare Battersby
Bhash Parasuraman
Stuart McIntosh
Faith Nathan
Elisabeth C Piault
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2011
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-9-88

Other articles of this Issue 1/2011

Health and Quality of Life Outcomes 1/2011 Go to the issue

Research

Relationships between changes in pain severity and other patient-reported outcomes: an analysis in patients with posttraumatic peripheral neuropathic pain

Research

Performance and cross-cultural comparison of the short-form version of the CPQ11-14 in New Zealand, Brunei and Brazil

Research

Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients

Research

Differential aspects of stroke and congestive heart failure in quality of life reduction: a case series with three comparison groups

Research

The influence of the level of physical activity and human development in the quality of life in survivors of stroke

Research

Determinants of quality of life in adults with type 1 and type 2 diabetes